Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy by Boros, András Mihály et al.
Research Article
Measurement of the Red Blood Cell
Distribution Width Improves the Risk Prediction in
Cardiac Resynchronization Therapy
András Mihály Boros,1 Péter Perge,1 Zsigmond Jenei,2 Júlia Karády,1
Endre Zima,1 Levente Molnár,1 Dávid Becker,1 László Gellér,1 Zoltán Prohászka,2
Béla Merkely,1 and Gábor Széplaki1
1Heart and Vascular Center, Semmelweis University, Va´rosmajor Utca 68, Budapest 1122, Hungary
2Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary
Correspondence should be addressed to Be´la Merkely; merkely.bela@kardio.sote.hu
Received 14 October 2015; Revised 7 December 2015; Accepted 24 December 2015
Academic Editor: Alberto Marra
Copyright © 2016 Andra´s Miha´ly Boros et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Objectives. Increases in red blood cell distribution width (RDW) and NT-proBNP (N-terminal pro-B-type natriuretic peptide)
predict the mortality of chronic heart failure patients undergoing cardiac resynchronization therapy (CRT). It was hypothesized
that RDW is independent of and possibly even superior to NT-proBNP from the aspect of long-term mortality prediction. Design.
The blood counts and serum NT-proBNP levels of 134 patients undergoing CRT were measured. Multivariable Cox regression
models were applied and reclassification analyses were performed. Results. After separate adjustment to the basic model of left
bundle branch block, beta blocker therapy, and serum creatinine, both the RDW > 13.35% andNT-proBNP > 1975 pg/mL predicted
the 5-year mortality (𝑛 = 57). In the final model including all variables, the RDW [HR = 2.49 (1.27–4.86); 𝑝 = 0.008] remained a
significant predictor, whereas the NT-proBNP [HR = 1.18 (0.93–3.51); 𝑝 = 0.07] lost its predictive value. On addition of the RDW
measurement, a 64% net reclassification improvement and a 3% integrated discrimination improvement were achieved over the
NT-proBNP-adjusted basic model. Conclusions. Increased RDW levels accurately predict the long-term mortality of CRT patients
independently of NT-proBNP. Reclassification analysis revealed that the RDW improves the risk stratification and could enhance
the optimal patient selection for CRT.
1. Introduction
Chronic heart failure is characterized by reduced cardiac
contractility and an impaired stroke volume. These changes
activate the sympathetic nervous system and cause a volume
redistribution and overload. The intravascular fluid excess
elevates the concentrations of circulating natriuretic peptides,
such as the N-terminal pro-B-type natriuretic peptide (NT-
proBNP), to compensate the hemodynamic alterations. NT-
proBNP is therefore regarded as a disease-specific biomarker
and is routinely used in diagnosis, therapy guidance, and
prognosis estimation for chronic heart failure patients [1].
Nevertheless, NT-proBNP mirrors only the actual volume
homeostasis, which is a rather simplified aspect of the
multifaceted pathophysiology.
The red blood cell distribution width (RDW) is ameasure
of the variation of the erythrocyte size, and an increased
RDW is also linked to a poor prognosis in cardiovascular
diseases, such as coronary artery disease [2], acutemyocardial
infarction [3], stroke [4], and chronic heart failure [5–8].
Interestingly, diabetes mellitus [9], liver diseases [10], and
renal dysfunctions [11] may likewise lead to RDW elevations,
the available evidence therefore suggesting that an increased
RDW reflects the presence and extent of a systemic injury
caused by the underlying disease.
Cardiac resynchronization therapy (CRT) is widely used
to treat chronic heart failure patients with electromechanical
dyssynchrony and a deteriorating functional status [12]. It
is well established that CRT improves the cardiac function,
Hindawi Publishing Corporation
Disease Markers
Volume 2016, Article ID 7304538, 13 pages
http://dx.doi.org/10.1155/2016/7304538
2 Disease Markers
exerts reverse remodeling, and decreases the need for hospi-
talization, though the mortality remains rather high [13].
The aim of this study was to measure the RDW and NT-
proBNP levels before CRT, for we hypothesized that these
biomarkers, either alone or in combination, can predict the
long-term mortality following CRT. Indeed, it has recently
been demonstrated that increasing RDW levels predict mor-
tality before CRT, although it remained unclear whether the
NT-proBNP data would affect the strength of the prediction
[14–16]. Accordingly, we performed multivariable survival
and reclassification analyses in order to determine the value
of the NT-proBNP and the RDW in the long-term prognosis
prediction.
2. Material and Methods
2.1. Study Population and Study Design. A cohort of 141 con-
secutive patients referred to our Heart and Vascular Center
between September 2009 and December 2010 was included
in this prospective single-center observational study. We
aimed to evaluate the prognostic impact of routine and novel
laboratory biomarkers in chronic heart failure patients with
CRT. We have shown previously the predictive role of white
blood cells in CRT [17]. The present analysis focuses on the
impact of the RDW in the same patient population.
CRT was indicated by medically refractory chronic heart
failure in accordance with the current guidelines [18]. Briefly,
the cohort comprised chronic heart failure patients on opti-
mal medical treatment with an impaired New York Heart
Association (NYHA) functional status (II–IV), a severely
reduced (<35%) left ventricular ejection fraction (LVEF),
and a wide QRS in the ECG (>120msec). Four patients
were excluded because of history of autoimmune disease,
hematologic disease, an acute or chronic inflammatory
disease, or a malignancy. Experienced electrophysiologists
performed the CRT by insertion of a left ventricular lead into
the coronary sinus and a right ventricular lead in a septal
position. Routine laboratory tests, clinical examinations, and
ECG and echocardiographic measurements were carried out
at baseline and 6 months later. Cardiologists analyzed the
echocardiographic parameters in a blinded fashion in order
to calculate the LVEF with Simpson’s biplane method and the
left ventricle volumes with the Teicholz method.
Prior to the enrollment, the local Ethics Committee of
the Semmelweis University had approved the protocol, which
was in accordance with the Helsinki Declaration, and all of
the patients provided their written informed consent.
Complete laboratory and echocardiographic data on a
total of 134 patients were included in the final analysis. The
all-cause 5-year mortality was taken as the end-point of the
study. Echocardiographic reverse remodeling was defined as
an improvement of at least 15% in the left ventricular end-
systolic volume 6 months after CRT implantation without
death.
2.2. Laboratory Measurements. Study personnel collected
ethylenediaminetetraacetic acid and citrate-treated serum
samples for routine biochemical measurements before CRT
and 6 months later. Red blood cell morphology parameters
were recorded with the Symex XS-1000i (Kobe, Japan) sys-
tem by means of a direct current detection method and
hydrodynamic focusing technology. Levels of NT-proBNP
were measured with an electrochemiluminescence Cobas e
411 analyzer (Mannheim, Germany), using Roche Elecsys
NT-proBNP II kits (Cat. number: 04842464190, Mannheim,
Germany).
2.3. Statistical Analysis. A two-tailed 𝑝 value of < 0.05 was
considered statistically significant in all cases. The statistical
analysis was carried out by using IBM SPSS 22 (Apache Soft-
ware Foundation, USA), Graphpad Prism 6.03 (GraphPad
Softwares Inc, USA), and PASS 2008 (NCSS, USA) the open
source R software (R version 3.1.2 with PredictABEL and
pROC packages).
The data were expressed as medians with interquartile
ranges or as percentages with event numbers and the Mann-
Whitney test or the chi squared test was applied for the
comparison of two groups, as appropriate. Univariate Cox
regression analysis was used to determine the 5-year mortal-
ity predictors.The continuous variables were standardized by
a one standard deviation (SD) increase (𝑍 transformation).
Receiver operating characteristic analysis was used and the
continuous variables were dichotomized in such a way as
to obtain identical sensitivity values, and the Kaplan-Meier
curves were then compared by using log-rank tests. In
the multivariable Cox regression models, the basic model
included variables with 𝑝 < 0.05 values of the univariate
analysis, and further adjusted models were built in a forward
stepwise manner [19]. A second multivariable model was
performed with factors that gave 𝑝 < 0.15 in the univariate
analysis in order to present a broader view of the prediction.
Power analysis was performed, and the validity of the results
was checked and the performance of the models was char-
acterized via the Brier score and Nagelkerke’s 𝑅2. Finally, 𝐶-
statistics with the DeLong test was carried out to display the
overall areas under the curves of the models and for reclassi-
fication analyses, including net reclassification improvement
(NRI) and integrated discrimination improvement (IDI)
[20].
3. Results
3.1. Baseline Characteristics of the Study Population. The
median age of the 134 patients was 67 years, 82% of themwere
male, 57% had ischemic heart failure, and 82% exhibited a left
bundle branch block (LBBB) in the ECG, as shown in Table 1.
3.2. Changes in Echocardiographic and Laboratory Parameters.
The patients experienced echocardiographic reverse remod-
eling 6months after CRT implantation. LVEF increased [28%
(23–33) versus 37% (30–41); 𝑝 < 0.0001], while LVESV [210
(153–276) versus 167 (115–242)mL; 𝑝 < 0.0001] and LVEDV
[303 (250–361) versus 259 (202–324)mL; 𝑝 < 0.0001]
decreased statistically significantly. The RDW, hematocrit,
and creatinine remained statistically unaltered [13.6% (13.0–
14.6) versus 13.4% (13.0–14.2);𝑝 = 0.56 and 42.3% (38.2–45.0)
versus 41.4% (38.3–43.4); 𝑝 = 0.06, and 109 (79–134) versus
96 (80–130) 𝜇mol/L; 𝑝 = 0.73, resp.], whereas NT-proBNP
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Table 1: Baseline parameters as predictors of the 5-year mortality.
Heart failure
patients Survived (𝑛 = 77) Died (𝑛 = 57) 𝑝 value
Five-year mortality
(𝑛 = 134) HR 95% CI of HR Wald 𝜒2 𝑝 value
Clinical variables
Age (years) 67 (60–73) 67 (60–71) 70 (62–74) 0.08 1.28 0.96–1.71 2.99 0.08
Male gender 110 (82) 59 (76) 51 (89) 0.05 2.06 0.88–4.81 2.82 0.09
BMI (kg/m2) 27 (24–30) 27 (25–30) 27 (23–29) 0.14 0.82 0.63–1.07 2.01 0.15
Ischemic 77 (57) 41 (53) 36 (63) 0.25 1.36 0.79–2.33 1.27 0.25
LBBB 110 (82) 70 (90) 40 (70) 0.002 0.35 0.20–0.63 12.52 <0.0001
CRT-D 22 (16) 14 (18) 8 (14) 0.52 0.72 0.34–1.54 0.68 0.40
Opt. lead position 98 (73) 56 (72) 42 (73) 0.90 1.00 0.55–1.80 0.00 1.00
QRS (msec) 163 (140–184) 164 (140–184) 163 (142–185) 0.82 1.05 0.81–1.36 0.14 0.70
LVEF (%) 28 (23–33) 28 (23–32) 26 (23–33) 0.90 0.96 0.73–1.27 0.05 0.82
LVESV (mL) 210 (153–276) 218 (158–276) 202 (140–259) 0.30 0.90 0.68–1.20 0.45 0.50
LVEDV (mL) 303 (250–361) 308 (250–381) 294 (242–341) 0.39 0.90 0.69–1.18 0.50 0.47
NYHA III, IV 115 (85) 63 (81) 52 (91) 0.12 2.07 0.82–5.19 2.42 0.12
Hypertension 70 (52) 42 (54) 32 (56) 0.85 1.04 0.61–1.75 0.02 0.88
Hyperlipidemia 32 (23) 16 (20) 16 (28) 0.32 1.20 0.67–2.14 0.39 0.53
Diabetes m. 48 (35) 26 (33) 24 (42) 0.32 1.51 0.89–2.56 2.36 0.12
ACEi/ARB 128 (95) 75 (97) 53 (92) 0.22 0.54 0.19–1.49 1.39 0.23
BB 119 (88) 73 (94) 47 (82) 0.02 0.34 0.17–0.69 9.11 0.003
MRI 93 (69) 57 (74) 37 (64) 0.25 0.71 0.41–1.23 1.46 0.22
Laboratory data
RDW (%) 13.6 (13.0–14.6) 13.3 (12.9–14.0) 14.2 (13.5–15.2) <0.0001 1.48 1.25–1.75 20.89 <0.0001
Hematocrit (%) 42 (38–45) 42 (39–45) 40 (36–43) 0.01 0.70 0.53–0.92 6.21 0.01
NT-proBNP (pg/mL) 2612 (1454–5101) 2188 (997–3567) 4025 (2086–6482) <0.0001 1.43 1.19–1.73 14.45 <0.0001
Creatinine (𝜇mol/L) 109 (79–134) 93 (74–113) 116 (91–148) 0.0002 1.42 1.18–1.71 14.25 <0.0001
Data are expressed as medians with interquartile ranges for continuous variables and as event numbers with percentages for categorical variables. For the
comparison of continuous data, we used the Mann-Whitney test, whereas the chi squared test was applied for the comparison of the categorical variables. The
5-year mortality was assessed by using univariate Cox regression analysis. The hazard ratios refer to the presence versus the absence in the case of categorical
variables and a 1 standard deviation increase in the case of continuous variables. HR= hazard ratio; CI = confidence interval;𝜒2 =Wald chi squared; BMI = body
mass index; Ischemic = ischemic etiology of the heart failure; LBBB = left bundle branch block; CRT-D = cardiac resynchronization therapy with implantable
cardioverter defibrillator; Opt. lead position = lateral or posterolateral position; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic
volume; LVEDV = left ventricular end diastolic volume; NYHA III, IV = New York Heart Association classification 3-4; ACEi/ARB = angiotensin convertase
inhibitor/angiotensin receptor blocker; BB = beta-blocker; MRI = mineralocorticoid receptor inhibitor; NT-proBNP = N-terminal of the prohormone brain
natriuretic peptide; RDW = red blood cell distribution width.
decreased significantly [2612 (1454–5101) versus 1626 (725–
3300) pg/mL; 𝑝 < 0.0001]. Figure 1 illustrates the baseline
RDW and NT-proBNP distributions.
A total of 123 patients were analyzed for reverse remod-
eling. The responders to CRT (𝑛 = 61, 50%) were younger
and presented with higher left ventricular volumes, a better
NYHA functional status, and more frequent MRI usage, as
described in Table 2. Increasing baseline levels of RDW [odds
ratio (OR) = 1.52 (1.01–2.29);𝑝 = 0.04, per 1 SD increase], NT-
proBNP [OR = 2.00 (1.19–3.38); 𝑝 = 0.009] and creatinine
[OR = 1.56 (1.04–2.34); 𝑝 = 0.02] predicted the lack of reverse
remodeling (𝑛 = 62, 50%) in univariate logistic regression
analysis. Hematocrit concentrations were not associated with
reverse remodeling [OR = 0.70 (0.49–1.02); 𝑝 = 0.06]. In
the multivariable analysis involving the significant factors
(𝑝 < 0.05) of the univariate models, only NT-proBNP [OR =
2.67 (1.06–6.69); 𝑝 = 0.03] remained statistically significant
laboratory predictor of a nonresponse [creatinine OR = 1.46
(0.90–2.41); 𝑝 = 0.12 and RDW OR = 1.01 (0.62–0.63); 𝑝 =
0.95].
3.3. Survival Analysis. Up to a median follow-up of 1799 days
(maximum 2181 days), 57 (42%) patients died (Table 1).Those
patients survived longer, who displayed LBBBmorphology in
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Table 2: Baseline parameters as predictors of the 6-month reverse remodeling.
Responders (𝑁 = 61) Nonresponders (𝑁 = 62) 𝑝 value Lack of reverse remodeling
OR 95% CI of OR Wald 𝜒2 𝑝 value
Clinical variables
Age (years) 65 (56–70) 68 (63–75) 0.003 1.84 1.22–2.78 8.51 0.004
Male gender 47 (77) 54 (87) 0.14 2.01 0.77–5.21 2.06 0.15
BMI (kg/m2) 27 (25–30) 27 (24–30) 0.68 0.89 0.62–1.28 0.37 0.53
Ischemic 33 (54) 41 (66) 0.17 1.65 0.80–3.43 1.84 0.17
LBBB 54 (88) 49 (79) 0.15 0.48 0.18–1.32 1.98 0.15
CRT-D 11 (18) 8 (12) 0.43 0.67 0.25–1.81 0.61 0.43
Opt. lead position 44 (72) 44 (70) 0.88 0.94 0.43–2.06 0.02 0.88
QRS (msec) 160 (160–180) 160 (140–181) 0.62 0.89 0.62–1.28 0.35 0.55
LVEF (%) 27 (22–31) 27 (23–33) 0.63 1.12 0.78–1.58 0.40 0.52
LVESV (mL) 234 (173–276) 188 (137–238) 0.01 0.63 0.42–0.94 5.01 0.01
LVEDV (mL) 331 (263–386) 267 (234–336) 0.006 0.62 0.42–0.91 5.91 0.01
NYHA III. IV 47 (77) 58 (93) 0.01 4.31 1.33–13.99 5.94 0.01
Hypertension 32 (52) 34 (54) 0.79 1.10 0.54–2.26 0.70 0.79
Hyperlipidemia 12 (19) 19 (30) 0.16 1.80 0.78–4.14 1.93 0.16
Diabetes m. 20 (32) 24 (38) 0.49 1.29 0.61–2.71 0.46 0.49
ACEi/ARB 58 (95) 60 (96) 0.63 1.55 0.25–9.62 0.22 0.63
BB 58 (95) 56 (90) 0.19 0.40 0.10–1.65 1.58 0.20
MRI 49 (80) 37 (59) 0.01 0.36 0.16–0.81 6.03 0.01
Laboratory data
RDW (%) 13.4 (12.8–14.1) 13.9 (13.0–14.9) 0.01 1.52 1.01–2.29 4.07 0.04
Hematocrit (%) 42 (39–45) 40 (36–44) 0.06 0.70 0.49–1.02 3.35 0.06
NT-proBNP (pg/mL) 2277 (987–3627) 3126 (1665–6231) 0.002 2.00 1.19–3.38 6.88 0.009
Creatinine (𝜇mol/L) 96 (73–131) 113 (82–143) 0.03 1.56 1.04–2.34 4.75 0.02
Data are expressed as medians with interquartile ranges for continuous variables and as event numbers with percentages for categorical variables. For the
comparison of continuous data, we used the Mann-Whitney test, whereas the chi squared test was applied for the comparison of the categorical variables.
Reverse remodeling was defined as a relative decrease of at least 15% in the LVESV 6 months after CRT implantation without death. The lack of reverse
remodeling was tested by using univariate logistic regression analyses. The odds ratios refer to the presence versus the absence in the case of categorical
variables and a 1 standard deviation increase in the case of continuous variables. OR = odds ratio; CI = confidence interval; 𝜒2 =Wald chi squared; BMI = body
mass index; Ischemic = ischemic etiology of the heart failure; LBBB = left bundle branch block; CRT-D = cardiac resynchronization therapy with implantable
cardioverter defibrillator; Opt. lead position = lateral or posterolateral position; LVEF = left ventricular ejection fraction; LVESV = left ventricular end systolic
volume; LVEDV = left ventricular end diastolic volume; NYHA III, IV = New York Heart Association classification 3-4; ACEi/ARB = angiotensin convertase
inhibitor/angiotensin receptor blocker; BB = beta-blocker; MRI = mineralocorticoid receptor inhibitor; NT-proBNP = N-terminal of the prohormone brain
natriuretic peptide; RDW = red blood cell distribution width.
the ECG or were on beta-blocker therapy. Increasing baseline
levels of RDW [hazard ratio (HR) = 1.48 (1.25–1.75), 𝑝 <
0.0001; per 1 SD increase], NT-proBNP [HR = 1.43 (1.19–
1.73); 𝑝 < 0.0001], and serum creatinine [HR = 1.42 (1.18–
1.71); 𝑝 < 0.0001] worsened the long-term survival chances.
Elevated hematocrit fractions improved the survival [HR =
0.70 (0.53–0.92); 𝑝 = 0.01]. Older age (𝑝 = 0.08), male
gender (𝑝 = 0.09), poor NYHA class, and diabetes mellitus
(𝑝 = 0.12) tended to be associated with an adverse outcome.
Receiver operating characteristic analysis was performed
to obtain optimal cut-off values. Each laboratory parameter
was dichotomized so as to reach a sensitivity of 79% (66–
88) in mortality prediction, which we considered clinically
meaningful. In this way, the individual specificity values were
different, but the sensitivity was the same in all cases, making
the cut-off selection more objective and comparable.
Patients before CRT were subject to up to a 3-fold
increased 5-year mortality risk, with RDW levels > l3.35%
[HR = 3.20 (1.69–6.06), 𝑝 = 0.0002; specificity = 53% (42–
65)], NT-proBNP levels > 1975 pg/mL [HR = 2.71 (1.43–5.14),
𝑝 = 0.001; specificity = 48% (37–60)] and serum creatinine >
88.5 𝜇mol/L [HR = 2.80 (1.45–5.42), 𝑝 = 0.001; specificity =
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Figure 1: Histogram of baseline RDWandNT-proBNP. Both the RDWandNT-proBNP differ from the red line of normal distribution. RDW
= red blood cell distribution width; NT-proBNP =N-terminal pro-B-type natriuretic peptide; SD = standard deviation; SEM= standard error
of the mean; IQR = interquartile range (25% percentile–75% percentile).
47% (35–59)], as shown in Figure 2. A hematocrit < 44% [HR
= 1.59 (0.84–3.00), 𝑝 = 0.15; specificity = 34% (24–45)] did
not predict mortality statistically significantly.
Patients with elevated RDW levels before CRT implanta-
tion were in a worse NYHA functional class, had less LBBB
pattern in the ECGwithwiderQRS, and used less angiotensin
convertase inhibitor therapy, as shown in Table 3. They also
tended to be older and to have diabetes more frequently.
These patients exhibited significantly elevated NT-proBNP
and creatinine concentrations but statistically indifferent
hematocrit levels.
We performedmultivariable Cox regression analyses and
set up a basic prediction model with significant (𝑝 < 0.05)
clinical (LBBB and beta-blocker therapy) and laboratory
parameters (serum creatinine > 88.5 𝜇mol/L). After separate
adjustment to the basic model, both the RDW > 13.35% [HR
= 2.81 (1.45–5.44); 𝑝 = 0.002] and NT-proBNP > 1975 pg/mL
[HR = 2.19 (1.13–4.23); 𝑝 = 0.01] predicted the 5-year
mortality (Table 4). In the final model including all variables,
the RDW remained significant [HR = 2.49 (1.27–4.86); 𝑝 =
0.008], whereas the NT-proBNP lost its predictive value [HR
= 1.18 (0.93–3.51); 𝑝 = 0.07].
We additionally implemented a multivariable model 2,
in which the basic model included extended clinical (age,
male gender, NYHA class III/IV, LBBB, beta-blocker therapy,
and diabetes mellitus) and laboratory (serum creatinine >
88.5 𝜇mol/L) factors with 𝑝 < 0.15 from the univariate
analysis (Table 5). Similarly, after separate adjustment to the
basic model, both the RDW > 13.35% [HR = 2.07 (1.38–5.29);
𝑝 = 0.004] and NT-proBNP > 1975 pg/mL [HR = 2.21 (1.13–
4.33); 𝑝 = 0.02] predicted the 5-year mortality. In the final
model including all variables, the RDW remained significant
[HR = 2.42 (1.22–4.76); 𝑝 = 0.01], whereas the NT-proBNP
lost its predictive value [HR = 1.88 (0.95–3.69); 𝑝 = 0.06].
3.4. Validation, Performance, and Reclassification. The power
analysis demonstrated that the RDW had a predictive power
of 84% in the population of 134 patients to detect those 45
patients who died with an elevated RDW. The predicted and
observed risks, assessed with the Hosmer-Lemeshow test,
were similar throughout the analyses, as an indication of good
calibration and confirming the validity (Figure 3, Tables 4 and
5). The Brier Score and Nagelkerke 𝑅2 measure the accuracy
of survival predictions.The changes (a decreasing Brier score
and an increasing Nagelkerke 𝑅2) in these scores suggest an
improved prediction (Tables 4 and 5).
The 𝐶-statistics measures the overall areas under the
curve (AUC) of the prediction models. Both the RDW [AUC
= 0.71 to 0.75; 𝑝 = 0.03] andNT-proBNP [AUC= 0.71 to 0.74;
𝑝 = 0.04] improved the prediction statistically significantly
beyond the basic model (Figure 4 and Table 4).
By adding RDW, we reached a reclassification improve-
ment of 64% [NR I = 0.64 (0.33–0.95); 𝑝 < 0.0001] and a
discrimination development of a 3% [IDI = 0.03 (0.00–0.07),
𝑝 = 0.01] over the NT-proBNP-adjusted basic model. Setting
the NT-proBNP into the RDW-adjusted basic model did not
result in such an improvement [NRI = 0.14 (−0.03–0.33); 𝑝 =
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Table 3: Differences in baseline characteristics in patients with increased or decreased RDW levels.
RDW <
13.35%
RDW > 13.35%
𝑝 value
(𝑛 = 53) (𝑛 = 81)
Clinical variables
Age (years) 67 (59–71) 68 (62–74) 0.08
Male gender 43 (81) 67 (82) 0.81
BMI (kg/m2) 27 (24–30) 27 (23–29) 0.40
Ischemic 30 (56) 47 (58) 0.87
LBBB 49 (92) 61 (75) 0.005
CRT-D 11 (20) 11 (13) 0.27
Opt. lead position 41 (77) 57 (70) 0.37
QRS (msec) 155
(134–180)
164 (146–189) 0.04
LVEF (%) 28 (24–33) 25 (23–32) 0.43
LVESV (mL) 202
(147–276)
214 (153–267) 0.71
LVEDV (mL) 285
(234–341)
312 (250–361) 0.29
NYHA III. IV 40 (75) 75 (92) 0.005
Hypertension 29 (54) 45 (55) 0.92
Hyperlipidemia 11 (20) 21 (25) 0.49
Diabetes m. 15 (28) 35 (43) 0.08
ACEi/ARB 53 (100) 75 (92) 0.04
BB 49 (92) 71 (87) 0.37
MRI 37 (69) 57 (70) 0.94
Laboratory data
Hematocrit (%) 43 (39–45) 41 (37–43) 0.11
NT-proBNP (pg/mL) 1817
(691–3086)
3581 (2007–6232) <0.0001
Creatinine (𝜇mol/L) 92 (74–121) 112 (85–135) 0.007
Data are expressed as medians with interquartile ranges for continuous variables and as event numbers with percentages for categorical variables. For the
comparison of continuous data, we used the Mann-Whitney test, whereas the chi squared test was applied for the comparison of the categorical variables.
BMI = body mass index; Ischemic = ischemic etiology of the heart failure; LBBB = left bundle branch block; CRT-D = cardiac resynchronization therapy
with implantable cardioverter defibrillator; Opt. lead position = lateral or posterolateral position; LVEF = left ventricular ejection fraction; LVESV = left
ventricular end systolic volume; LVEDV = left ventricular end diastolic volume; NYHA III, IV = New York Heart Association classification 3-4; ACEi/ARB =
angiotensin convertase inhibitor/angiotensin receptor blocker; BB = beta-blocker; MRI = mineralocorticoid receptor inhibitor; NT-proBNP = N-terminal of
the prohormone brain natriuretic peptide; RDW = red blood cell distribution width.
0.11 and IDI = 0.01 (−0.01–0.03); 𝑝 = 0.20], as demonstrated
in Table 4. The multivariable model 2 suggested similar
results (Table 5).
The IDI = 0.03 indicates that 3% of the patients would
have been better categorized by using the RDW in the final
model: 4 of the 134 patients presented with low NT-proBNP
but high RDW and died 5 years later. Figure 5 displays this
improved discrimination capacity; the median mortality risk
[𝑝 = 0.42 (57/134)] decreases in patients categorized as future
survivors (𝑝 = 0.22) and increases in patients likely to die
(𝑝 = 0.55).
4. Discussion
4.1. Synopsis of Key Findings. We have shown that an
increased RDW predicts the long-term mortality of chronic
heart failure patients undergoing CRT, independently of
the NT-proBNP level or other factors. The reclassification
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Figure 2: Increased RDW and NT-proBNP levels predict the 5-year mortality of chronic heart failure patients before CRT. We performed
receiver operating characteristic analysis (a) and dichotomized the continuous variables so as to obtain the same sensitivity values.TheKaplan-
Meier survival curves were tested by the log-rank test (b). CRT = cardiac resynchronization therapy; RDW= red blood cell distribution width;
NT-proBNP =N-terminal pro-B-type natriuretic peptide; AUC = area under the curve; Sens = sensitivity; Spec = specificity; NPV = negative
predictive value; PPV = positive predictive value.
analyses revealed that theRDWhas a higher risk stratification
value than that of NT-proBNP in mortality prediction.
Increased baseline RDW levels also predicted the lack of
echocardiographic reverse remodeling, but NT-proBNP was
superior from the aspect of CRT response prediction.
4.2. Possible Mechanisms and Explanations. Prediction mod-
els with RDW in chronic heart failure patients have been
previously investigated [5–8], but the underlying mechanism
remains unclear. Chronic heart failure is associated with
systemic inflammation, oxidative stress, cytokine produc-
tion, and neurohumoral activation, leading to enhanced
catecholamine release and sympathetic activation [21]. Cat-
echolamines downregulate renal erythropoietin production
and cause consecutive anemia [22]. On the other hand,
the sympathetic activation increases the cardiac output and
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Table 4: Multivariable Cox regression analysis of the 5-year mortality with validation, calibration, and reclassification.
Basic model
with RDW
+ NT-proBNP
Basic model
+ RDW Basic model
Basic model
+ NT-proBNP
Basic model with
NT-proBNP
+ RDW
Cox regression
HR of RDW 2.49
(1.27–4.86)
2.81
(1.45–5.44) 2.49 (1.27–4.86)
𝑝 (RDW) 0.008 0.002 0.008
HR of NT-proBNP 1.18 (0.93–3.51) 2.19 (1.13–4.23) 1.18 (0.93–3.51)
𝑝 (NT-proBNP) 0.07 0.01 0.07
Validation
Overall 𝜒2 42.62 40.47 29.86 35.32 42.62
𝑝 (overall) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
𝑝 (changes) 0.06 0.001 0.01 0.004
Calibration
HL test 𝜒2 8.26 6.72 0.48 4.01 8.26
𝑝 (HL test) 0.40 0.56 0.99 0.85 0.40
Performance
Brier score 0.18 0.19 0.20 0.19 0.18
Nagelkerke’s 𝑅2 0.30 0.28 0.21 0.26 0.30
Reclassification
𝐶-statistics 0.76
(0.69–0.84)
0.75
(0.66–0.83)
0.71
(0.63–0.79)
0.74
(0.66–0.82) 0.76 (0.69–0.84)
𝑝 (𝐶-statistics) 0.80 0.03 0.04 0.39
NRI (95% CI) 0.14
(–0.03–0.33)
0.64
(0.33–0.95)
0.54
(0.23–0.84) 0.64 (0.33–0.95)
𝑝 (NRI) 0.11 <0.0001 0.0005 <0.0001
IDI (95% CI) 0.01
(–0.00–0.03)
0.05
(0.01–0.09)
0.03
(0.00–0.06) 0.03 (0.00–0.07)
𝑝 (IDI) 0.20 0.003 0.04 0.01
The basic multivariable Cox regression model included left bundle branch block, beta-blocker therapy, and creatinine > 88.5𝜇mol/L. The RDW > 13.35% and
NT-proBNP > 1975 pg/mL were adjusted separately to the basic model in a forward stepwise manner. The final common model included all variables. HR =
hazard ratio; 𝜒2 = chi squared; HL test = Hosmer-Lemeshow test; 95% CI = 95% confidence interval; 𝐶-statistics = overall areas under the curve, assessed
by the DeLong test; NRI = net reclassification improvement; IDI = integrated discrimination improvement. NT-proBNP = N-terminal pro-B-type natriuretic
peptide; RDW = red blood cell distribution width.
stroke volume resulting in a volume redistribution that
reduces the renal blood flow [22]. Furthermore, the upreg-
ulated plasma corticosteroids suppress the hematopoiesis
in the bone marrow [23]. Development of the “cardiorenal
syndrome” is characterized by anemia and a renal dysfunc-
tion. We therefore adjusted the serum creatinine data in the
prediction models so as to reduce the possible influence of a
renal dysfunction on the RDW values.
Very intensive clinical research is ongoing for biomarkers
that predict the long-term survival of CRT patients, and
biostatistics has a decisive role in these investigations [12].
Themost commonly used method is Cox regression analysis,
though it is of limited value in real clinical benefit assess-
ments, as it overestimates the prediction if not controlled
[24]. In contrast, the 𝐶-statistics, which investigates the
overall AUCs of the models, is a rather conservative method
and underestimates the benefit [24]. Novel reclassification
approaches have therefore been developed, that is, NRI and
IDI, to reveal the absolute discrimination improvement [20].
In our analysis we made use of well-calibrated prediction
models, and the results of 𝐶-statistics, NRI, and IDI con-
firmed the results of the Cox regression analysis.
A recent systematic meta-analysis demonstrated that
increased RDW levels are associated with a poor prognosis
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Table 5: Multivariable Cox regression analysis 2 of the 5-year survival with validation, calibration, and reclassification.
Basic model
with RDW
+ NT-proBNP
Basic model
+ RDW Basic model
Basic model
+ NT-proBNP
Basic model with
NT-proBNP
+ RDW
Cox regression
HR of RDW 2.42
(1.22–4.76)
2.07
(1.38–5.29) 2.42 (1.22–4.76)
𝑝 (RDW) 0.01 0.004 0.01
HR of NT-proBNP 1.88
(0.95–3.69) 2.21 (1.13–4.33) 1.88 (0.95–3.69)
𝑝 (NT-proBNP) 0.06 0.02 0.06
Validation
Overall 𝜒2 46.08 43.52 33.90 39.10 46.08
𝑝 (overall) <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
𝑝 (changes) 0.05 0.002 0.01 0.006
Calibration
HL test 𝜒2 4.65 1.78 11.75 4.71 4.65
𝑝 (HL test) 0.79 0.98 0.16 0.78 0.79
Performance
Brier score 0.18 0.18 0.19 0.19 0.18
Nagelkerke’s 𝑅2 0.34 0.32 0.25 0.29 0.34
Reclassification
𝐶-statistics 0.80
(0.72–0.87)
0.78
(0.70–0.85)
0.74
(0.66–0.82)
0.76
(0.68–0.84) 0.80 (0.72–0.87)
𝑝(𝐶-statistics) 0.39 0.20 0.29 0.11
NRI (95% CI) 0.24
(–0.03–0.34)
0.64
(0.33–0.95)
0.54
(0.23–0.84) 0.64 (0.33–0.95)
𝑝 (NRI) 0.19 <0.0001 0.0005 <0.0001
IDI (95% CI) 0.01
(–0.01–0.03)
0.05
(0.01–0.09)
0.03
(−0.00–0.06) 0.04 (0.01–0.07)
𝑝 (IDI) 0.18 0.004 0.05 0.01
The basic multivariable Cox regression model included age, male gender, NYHA class III/IV, LBBB, beta-blocker therapy, diabetes mellitus, and creatinine >
88.5𝜇mol/L. The RDW > 13.35% and NT-proBNP > 1975 pg/mL were adjusted separately to the basic model in a forward stepwise manner. The final common
model included all variables. HR = hazard ratio; 𝜒2 = chi squared; HL test = Hosmer-Lemeshow test; 95% CI = 95% confidence interval; 𝐶-statistics = overall
areas under the curve, assessed by the DeLong test; NRI = net reclassification improvement; IDI = integrated discrimination improvement. NT-proBNP = N-
terminal pro-B-type natriuretic peptide; RDW = red blood cell distribution width.
in patients with chronic heart failure [8] and also concluded
that natriuretic peptides affect mortality, so that the prog-
nostic value of the RDW might be overestimated without
adjustment to NT-proBNP. In fact, our data reveal that
the predictive value of NT-proBNP might be overestimated
without adjustment to the RDW. It should be added that
appropriately performed survival analyses are mandatory if
a firm conclusion is to be reached.
To date, only three studies have evaluated the role of
RDW in mortality prediction of CRT patients [14–16]. In a
study on 217 patients, Rickard et al. demonstrated that the
presence of an elevated RDW is associated with an increased
mortality risk and less reverse left ventricular remodeling
in patients undergoing CRT [15]. Celikyurt et al. showed
that RDW fractions were increased significantly 6 months
after CRT in the nonresponders among 66 patients but
remained unaltered in the responders [14]. The investigation
by Topaz et al. on 156 patients indicated that increased
RDW levels even 6 months and 12 months after implantation
are associated with poor mortality [16]. The baseline RDW
fractions proved to be strong and independent predictor
factors, but these studies did not investigate the influence of
NT-proBNP on the final outcome. Our study confirms and
extends these previous findings. The Cox regression results
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Figure 3: Calibration plots of the prediction models. The observed and predicted risks converge to the line of perfect prediction, suggesting
the good calibration of the models. RDW = red blood cell distribution width; NT-proBNP = N-terminal pro-B-type natriuretic peptide.
were validated with reclassification analyses, and the data
demonstrated that the RDW outperforms NT-proBNP in
long-term prediction. A possible explanation could be that
while the natriuretic peptides reflect the actual filling status of
the heart and determine the short-term outcome, the RDW
mirrors the extent of systemic injury and consequently the
long-term outcome. Further, the half-life of NT-proBNP is
approximately 25 minutes, whereas the RDW is associated
with the history of the previous 130 days (i.e., the lifespan
of the red blood cells); the natriuretic peptides may therefore
vary rapidly in response to current influences, while theRDW
may remain unchanged [25, 26].
In our study patients with elevated RDW levels before
CRT implantation were in worse NYHA functional class, had
less LBBB pattern in the ECG with wider QRS, and used
less angiotensin convertase inhibitor medications. They also
tended to be older and to have diabetes more frequently. The
RDW elevation is therefore most likely the consequence of
the multiple comorbidities and disease progression, being a
nonspecific biomarker. Nevertheless, reclassification analyses
considered these confounders and RDW was still able to
expand the risk prediction.
We established earlier that the ratio of the neutrophil
leucocytes to the lymphocytes (the NL ratio) predicts the
mortality in CRT independently of theNT-proBNP level [17].
We therefore propose that nonspecific biomarkers (such as
the NL ratio or the RDW)might be considered in the clinical
risk assessment scenarios. We in no way wish to underes-
timate the relevance of NT-proBNP measurements, but we
would like to point out that a single, simple blood parameter
could provide valuable additional prognostic information.
4.3. Strengths and Limitations. The main strength of this
study is that it show for the first time the additional value of
the RDW, a widely available biomarker in the risk assessment
for CRT patients. The results clearly demonstrate the benefit
of the RDW in risk prediction in a clinical setting. The
investigation is limited by the relatively small sample size,
which may have resulted in lower sensitivity and specificity.
Moreover, the present results reported here derive from the
analysis of an earlier published study by our group. All-
cause mortality was taken as the end-point of the study
and a distinction was not made between cardiovascular
and noncardiovascular death due to low event numbers.
The Teicholz method was used to compute left ventricular
volumes instead of Simpson’s method. Finally, the baseline
characteristics of the two RDW groups differed; nevertheless
the reclassification analyses considered these confounders.
The present investigation was obviously unable to
include all relevant factors affecting the outcome in CRT,
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Figure 4: Increasing predictive capacity of the models. The 𝐶-statistics measures the overall AUCs of the prediction models and displays the
overall predictive powers of the models in a more conservative fashion than Cox regression. AUC = area under the curve; RDW = red blood
cell distribution width; NT-proBNP = N-terminal pro-B-type natriuretic peptide.
which might also bias the results. This analysis is mainly
hypothesis-generating and the results should be regarded
therefore as preliminary. Larger trials are needed to confirm
the results.
5. Conclusions
Increased RDW levels predict the 5-year mortality of CRT
patients independently of the NT-proBNP concentrations.
Reclassification analysis revealed that the RDW might result
in a better risk stratification than that with NT-proBNP and
could lead to a better patient selection for CRT.
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Figure 5: Improved discrimination of the prediction models. The improved discrimination capacity is graphically visualized by means of
a box and whiskers diagram. The median (red line) of the mortality risk decreases in patients categorized as future survivors and increases
in patients likely to die. The dotted line indicates the baseline risk. RDW = red blood cell distribution width; NT-proBNP = N-terminal
pro-B-type natriuretic peptide.
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